Sarcoma
Sarcomas are characterized by their aggressive behavior, propensity to metastasize, and limited therapy options. Our company is an esteemed leader in the field of biological research and drug development, we are committed to providing state-of-the-art services for sarcoma drug and therapy development.
Introduction to Sarcoma
Sarcoma, a rare form of malignant tumor, arises from the mesenchymal cells encompassing various connective tissues, including bone, cartilage, fat, and vascular tissues. This group of tumors can manifest in both bone and soft tissues, giving rise to a diverse range of subtypes. Within bone sarcomas, prevalent subtypes include osteosarcoma, chondrosarcoma, Ewing sarcoma, and chordoma. Soft tissue sarcomas include liposarcoma, leiomyosarcoma, malignant peripheral nerve sheath tumor, rhabdomyosarcoma, and synovial sarcoma.
Pathogenesis of Sarcoma
- Exposure to ionizing radiation, such as prior radiation therapy, is a well-documented risk factor for both bone and soft tissue sarcomas.
- Certain inherited genetic syndromes, including inherited RB1 gene mutations, Li-Fraumeni syndrome, and Paget's disease of bone, have been linked to an elevated risk of developing sarcomas.
- Exposure to specific substances such as vinyl chloride, arsenic, and Thorotrast has been associated with an increased risk of certain sarcoma subtypes, like angiosarcoma.
Fig. 1 Diversity of sarcomas as highlighted by DNA methylation profiling. (Grünewald, Thomas GP, et al., 2020)Targeted Therapies of Sarcoma
Tyrosine Kinase Receptors
Abnormal activation of tyrosine kinase receptors, such as PDGFR, c-Kit, and VEGFR, is associated with sarcoma progression. Inhibitors targeting these receptors have shown promise in trials.
DNA Repair Pathways
Defects in DNA repair mechanisms are frequently observed in sarcomas. Targeting these pathways, such as PARP inhibitors, has emerged as a potential therapeutic strategy.
Immune Checkpoints
The immune system plays a crucial role in tumor surveillance. Immune checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 antibodies, have demonstrated efficacy in specific sarcoma subtypes.
Epigenetic Regulators
Dysregulation of epigenetic modifications is commonly observed in sarcomas. Targeting enzymes involved in histone modifications and DNA methylation holds promise in altering the tumor epigenome.
Our Services
Through comprehensive research and collaborative efforts, we delve into groundbreaking diagnostic strategies that focus on diverse molecular pathways implicated in the advancement of sarcoma. Our objective is to deliver specialized diagnostics for sarcoma and to facilitate the development of innovative therapeutic solutions.
Types of Sarcoma
Therapy Development Platforms
Our company is dedicated to the creation of robust and clinically significant animal models that faithfully mimic the attributes of human sarcomas. These models serve as invaluable tools in assessing the efficacy of potential therapies, enabling us to identify promising candidates for further advancement.
If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Grünewald, Thomas GP, et al. "Sarcoma treatment in the era of molecular medicine." EMBO molecular medicine 12.11 (2020): e11131.
- Damerell, Victoria, Michael S. Pepper, and Sharon Prince. "Molecular mechanisms underpinning sarcomas and implications for current and future therapy." Signal transduction and targeted therapy 6.1 (2021): 246.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.